Exelixis Receives Priority Review for Cancer Drug Indication

The FDA granted priority review to the application for an additional indication for the Exelixis cancer drug Cabometyx (cabozantinib).

The application is for approval of the drug for patients with previously untreated advanced renal cell carcinoma (RCC). The FDA action date on the application is Feb. 15, 2018.

Cabometyx was approved in 2016 for patients with advanced RCC who have received prior anti-angiogenic therapy.